パーキンソン病（PD）は慢性進行性の疾患で、特発性と考えられており、パーキンソニズム（運動障害を伴う神経疾患）の約80％を占めています。パーキンソン病の正確な原因は不明ですが、加齢、環境要因・暴露、遺伝的素因など、さまざまな要因が考えられます。
現在の治療法は、脳内のドーパミン濃度の管理が中心であり、レボドパをベースとした治療法は、過去半世紀にわたりパーキンソン病市場における標準的な治療法となっています。これらの治療法は、低い年間治療費（ACOT）で最もよく症状を緩和することができ、Sinemet（カルビドパ／レボドパ）とMadopar（ベンセラジド／レボドパ）の2つが最も人気のあるブランド薬となっています。
GlobalData社は、世界のパーキンソン病市場は予測期間中に大きな成長を遂げると予想しています。世界の売上高は、2019年の35億ドルから2029年には115億ドルに増加し、年平均成長率（CAGR）は12.6%になると予測しています。この成長は、17の後期パイプライン製品の発売によって推進されると見込まれます。 最も売れると予想される治療薬は、Roche/Prothena社のPRX-002で、Novo Nordisk社のVictozaがそれに続くでしょう。PRX-002は、疾患修飾特性を備えたモノクローナル抗体です。インフルエンサー（KOL）はこの治療薬について楽観的であり、PD治療に革命をもたらす可能性があることを示唆しました。 また、VictozaのMOAは、確立された高い安全性プロファイルに加えて、潜在的な神経保護薬として高く評価されていました。
目次
Table of Contents
1 Parkinson’s Disease: Executive Summary
1.1 Parkinson’s Market Expected to Grow Significantly, Driven by New Launches
1.2 High Opportunities and High Risks for Disease-Modifying Therapies Entering the PD Market
1.3 Diverse Pipeline Agents Will Partially Address Key Unmet Needs
1.4 The Entry of Novel Biologics and Innovative Delivery Systems Will Shape the PD Market
1.5 What Do Physicians Think?
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.1.3 Mechanisms of Cell Death
3.2 Classification or Staging Systems
4 Epidemiology
4.1 Disease Background
4.2 Risk Factors and Comorbidities
4.3 Global and Historical Trends
4.4 Forecast Methodology
4.4.1 Sources
4.4.2 Forecast Assumptions and Methods
4.5 Epidemiological Forecast for PD (2019-2029)
4.5.1 Diagnosed Prevalent Cases of PD
4.5.2 Sex-Specific Diagnosed Prevalent Cases of PD
4.5.3 Age-Specific Diagnosed Prevalent Cases of PD
4.5.4 Diagnosed Prevalent Cases of PD by HY Clinical Staging
4.5.5 Diagnosed Prevalent Cases of PD by Type
4.6 Discussion
4.6.1 Epidemiological Forecast Insight
4.6.2 COVID-19 Impact
4.6.3 Limitations of Analysis
4.6.4 Strengths of Analysis
5 Disease Management
5.1 Diagnosis and Treatment Overview
5.2 KOL Insights on Disease Management
6 Competitive Assessment
6.1 Overview
7 Unmet Needs and Opportunity Assessment
7.1 Overview
7.2 Effective Treatment of Motor Complications - Dyskinesia, Off-Episodes, Gait, and Balance Problems
7.3 New Therapies for Non-motor Complications - Psychosis and Dementia
7.4 Neuroprotective/Disease-Modifying Agents
7.5 Improved Drug Formulations
8 R&D Strategies
8.1 Overview
8.1.1 Development of Novel Targets ─ mAbs Targeting α-synuclein, and Gene Therapies
8.1.2 Innovative Drug Delivery Systems
8.1.3 Secondary Indications and Drug Repurposing
8.1.4 Clinical Trial Design
8.1.5 Reliable Biomarkers of Disease Progression
8.1.6 Genetic Studies Required to Learn About Genetic Subtypes of PD
9 Pipeline Assessment
9.1 Overview
9.2 Promising Drugs in Clinical Development
10 Pipeline Valuation Analysis
10.1 Overview
10.2 Competitive Assessment
11 Current and Future Players
11.1 Overview
11.2 Deal-Making Trends
12 Market Outlook
12.1 Global Markets
12.1.1 Forecast
12.1.2 Drivers and Barriers - Global Issues
12.2 US
12.2.1 Forecast
12.2.2 Key Events
12.2.3 Drivers and Barriers
12.3 5EU
12.3.1 Forecast
12.3.2 Key Events
12.3.3 Drivers and Barriers
12.4 Japan
12.4.1 Forecast
12.4.2 Key Events
12.4.3 Drivers and Barriers
13 Appendix
List of Tables
Table 1: Parkinson’s Disease: Key Metrics in the 7MM
Table 2: Modified HY Scale of PD Symptoms
Table 3: Movement Disorder Society-Sponsored Revision of the Unified PD Rating Scale (MDS-UPDRS), 2008
Table 4: Risk Factors and Comorbidities of PD
Table 5: Treatment Guidelines for PD
Table 6: Parkinson’s Disease Market - Global Drivers and Barriers, 2019-2029
Table 7: Key Events Impacting Sales for Parkinson’s Disease in the US, 2019-2029
Table 8: Parkinson’s Disease Market - Drivers and Barriers in the US, 2019-2029
Table 9: Key Events Impacting Sales for Parkinson’s Disease in the 5EU, 2019-2029
Table 10: Parkinson’s Disease Market - Drivers and Barriers in the 5EU, 2019-2029
Table 11: Key Events Impacting Sales for PD in Japan, 2019-2029
Table 12: PD Market - Drivers and Barriers in Japan, 2019-2029
Table 13: High-Prescribing Physicians (non-KOLs) Surveyed, By Country
List of Figures
Figure 1: Global Sales Forecast by Country for Parkinson’s Disease in 2019 and 2029
Figure 2: Analysis of the Company Portfolio Gap in Parkinson’s Disease During the Forecast Period
Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to be Licensed for the Treatment of Parkinson’s Disease During the Forecast Period
Figure 4: 7MM, Diagnosed Prevalence (%) of PD, Both Sexes, Ages ≥18 Years, 2019
Figure 5: 7MM, Sources Used and Not Used to Forecast the Diagnosed Prevalent Cases of PD
Figure 6: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of PD Segmented by HY Clinical Staging
Figure 7: 7MM, Diagnosed Prevalent Cases of PD, N, Both Sexes, Ages ≥18 Years, 2019
Figure 8: 7MM, Diagnosed Prevalent Cases of PD, N, by Sex, Ages ≥18 Years, 2019
Figure 9: 7MM, Diagnosed Prevalent Cases of PD by Age, N, Both Sexes, 2019
Figure 10: 7MM, Diagnosed Prevalent Cases of PD by HY Clinical Staging, N, Both Sexes, Ages ≥18 Years, 2019
Figure 11: 7MM, Diagnosed Prevalent Cases of PD by Type, N, Both Sexes, Ages ≥18 Years, 2019
Figure 12: Treatment Algorithm for Parkinson’s Patients
Figure 13: Unmet Needs and Opportunities in PD
Figure 14: Pharmacokinetics of Levodopa
Figure 15: Overview of the Development Pipeline in Parkinson’s Disease
Figure 16: Key Late-Stage Trials for the Promising Pipeline Agents that GlobalData Expects to Be Licensed for PD in the 7MM During the Forecast Period
Figure 17: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for the Treatment of Parkinson’s Disease During the Forecast Period
Figure 18: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC, Sinemet
Figure 19: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC, Requip
Figure 20: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC, Nuplazid
Figure 21: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC, Azilect
Figure 22: Analysis of the Company Portfolio Gap in Parkinson’s Disease During the Forecast Period (2019-2029)
Figure 23: Global (7MM) Sales Forecast by Country for Parkinson’s Disease in 2019 and 2029
Figure 24: Sales Forecast by Class for Parkinson’s Disease in the US in 2019 and 2029
Figure 25: Sales Forecast by Class for Parkinson’s Disease in the 5EU in 2019 and 2029
Figure 26: Sales Forecast by Class for PD in Japan in 2019 and 2029
